FGFR2 Antibody (133706) [Alexa Fluor® 350]

• Reactivity: Mu
• Applications: WB, B/N
• Clone: 133706
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 350

FGFR2 Antibody (133706) [Alexa Fluor® 350] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse FGF R2α (IIIc)
  Extracellular domains
• Specificity: Detects IIIc isoforms of mouse FGF R2 in direct ELISAs and Western blots. Does not react with IIIb isoforms of recombinant mouse (rm) FGF R2. In direct ELISAs and Western blots, 100% cross-reactivity with IIIc isoforms of recombinant human (rh)
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for FGFR2 Antibody (133706) [Alexa Fluor® 350]

• BBDS
• BEK
• BFR-1
• CD332 antigen
• CD332
• CEK3
• CFD1
• craniofacial dysostosis 1
• EC 2.7.10
• EC 2.7.10.1
• ECT1
• FGF R2
• FGFR2
• fibroblast growth factor receptor 2
• FLJ98662
• Jackson-Weiss syndrome
• JWS
• Keratinocyte growth factor receptorreceptor like 14
• KGFR
• KSAM
• K-sam
• soluble FGFR4 variant 4
• TK14
• TK25

Background

Fibroblast growth factors (FGFs) comprise a family of at least eighteen structurally related proteins that are involved in a multitude of physiological and pathological cellular processes, including cell growth, differentiation, angiogenesis, wound healing and tumorigenesis. The biological activities of the FGFs are mediated by a family of type I transmembrane tyrosine kinases which undergo dimerization and autophosphorylation after ligand binding. Four distinct genes encoding closely related FGF receptors, FGF R1‑4, are known. All four genes for FGF Rs encode proteins with an N-terminal signal peptide, three immunoglobulin (Ig)-like domains, an acid‑box region containing a run of acidic residues between the IgI and IgII domains, a transmembrane domain and the split tyrosine-kinase domain. Multiple forms of FGF R1‑3 are generated by alternative splicing of the mRNAs. A frequent splicing event involving FGF R1 and 2 results in receptors containing all three Ig domains, referred to as the alpha  isoform, or only IgII and IgIII, referred to as the beta  isoform. Only the alpha  isoform has been identified for FGF R3 and FGF R4. Additional splicing events for FGF R1‑3, involving the C-terminal half of the IgIII domain encoded by two mutually exclusive alternative exons, generate FGF receptors with alternative IgIII domains (IIIb and IIIc). A IIIa isoform which is a secreted FGF binding protein containing only the N-terminal half of the IgIII domain plus some intron sequences has also been reported for FGF R1. Mutations in FGF R1‑3 have been found in patients with birth defects involving craniosynostosis. The complex patterns of expression of these receptors as well as the specificity of their interactions with the various FGF ligand family members are under investigation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.